Loading...
Market
Rapport Therapeutics revenue for fiscal year 2024
5
Resolution / Starting Odds
Below $100M • 33%
$100M-$200M • 33%
Above $200M • 33%
Company financial reports
Story
Rapport Therapeutics Prices IPO at $17, Raises $154M with 22% Gain
Jun 7, 2024, 11:20 AM
Rapport Therapeutics Inc. (RAPP) successfully priced its initial public offering (IPO) at $17 per share, raising $136 million. The IPO involved 8 million shares and the company opened trading at $18 per share, marking a 5.9% increase from the IPO price. The shares rose nearly 6% in their market debut, valuing the company at $636.8 million. Rapport Therapeutics, backed by Johnson & Johnson's venture capital arm, is a clinical-stage biotechnology company focused on developing precision neuromedicines for central nervous system disorders. The company's stock market debut reaped $154 million, and it posted a 22% gain in its NASDAQ debut.
View original story
Similar markets
Below $10 • 33%
$10 to $20 • 34%
Above $20 • 33%
Loss • 33%
Breakeven • 34%
Profit • 33%
Underperform • 33%
Match • 34%
Outperform • 33%
Below $50 million • 33%
$50 million to $100 million • 33%
Above $100 million • 34%
Below $50 • 33%
Between $50 and $100 • 33%
Above $100 • 33%
Below $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
Above $1.5 billion • 25%
Less than $200 million • 25%
$200 million to $300 million • 25%
$300 million to $400 million • 25%
More than $400 million • 25%
Less than $50 • 25%
$50 to $75 • 25%
$75 to $100 • 25%
More than $100 • 25%
Below $5 billion • 25%
$5 billion to $10 billion • 25%
$10 billion to $15 billion • 25%
Above $15 billion • 25%